MetaADEDB 2.0 @ LMMD
Etidronic Acid
(DBVJJBKOTRCVKF-UHFFFAOYSA-N)
Structure
SMILES
CC(P(=O)(O)O)(P(=O)(O)O)O
Type(s)
Approved
ATC code(s)
M05BA01; M05BB01
Molecular Formula:
C2H8O7P2
Molecular Weight:
206.028
Log P:
-0.9922
Hydrogen Bond Acceptor:
7
Hydrogen Bond Donor:
5
TPSA:
154.91
CAS Number(s):
2809-21-4
Synonym(s)
1.
Etidronic Acid
2.
EHDP
3.
Ethanehydroxydiphosphonate
4.
Etidronate
5.
Etidronate Disodium
6.
Sodium Etidronate
7.
(1-hydroxyethylene)diphosphonic acid
8.
(1-hydroxyethylene)diphosphonic acid, Tetrapotassium Salt
9.
1,1-hydroxyethylenediphosphonate
10.
1-Hydroxyethane-1,1-Diphosphonate
11.
1-Hydroxyethylidene-1,1-Bisphosphonate
12.
Dicalcium EHDP
13.
Dicalcium Etidronate
14.
Didronel
15.
Disodium 1-Hydroxyethylene Diphosphonate
16.
Disodium Etidronate
17.
Ethanehydroxyphosphate
18.
Etidronate, Tetrapotassium Salt
19.
HEDP
20.
HEDSPA
21.
Hydroxyethanediphosphonate
22.
Hydroxyethylidene Diphosphonic Acid
23.
Phosphonic acid, (1-hydroxyethylidene)bis-, disodium salt
24.
Xidifon
25.
Xidiphon
26.
Xydiphone
27.
1 Hydroxyethane 1,1 Diphosphonate
28.
1 Hydroxyethylidene 1,1 Bisphosphonate
29.
1,1 hydroxyethylenediphosphonate
30.
1-Hydroxyethylene Diphosphonate, Disodium
31.
Diphosphonate, Disodium 1-Hydroxyethylene
32.
Diphosphonic Acid, Hydroxyethylidene
33.
Disodium 1 Hydroxyethylene Diphosphonate
34.
EHDP, Dicalcium
35.
Etidronate, Dicalcium
36.
Etidronate, Disodium
37.
Etidronate, Sodium
38.
Salt Etidronate, Tetrapotassium
39.
Tetrapotassium Salt Etidronate
External Link(s)
MeSHD012968
PubChem Compound3305
BindingDB50115102
ChEBI4907
CHEMBLCHEMBL871
DrugBankDB01077
DrugCentral1098
IUPHAR/BPS Guide to PHARMACOLOGY7184
KEGGcpd:C07736
dr:D02373
Therapeutic Target DatabaseD00NNC
ZINC3830813
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1AtelectasisFAERS: 1US FAERS
2Blood alkaline phosphatase increasedFAERS: 1US FAERS
3Blood parathyroid hormone decreasedFAERS: 1US FAERS
4Bone density decreasedFAERS: 1US FAERS
5Feeding intoleranceFAERS: 1US FAERS
6FractureFAERS: 1SIDER
US FAERS
7HypercalciuriaFAERS: 1US FAERS
8Incorrect drug administration durationFAERS: 1US FAERS
9Musculoskeletal DeformityFAERS: 1US FAERS
10OsteomalaciaFAERS: 1SIDER
US FAERS
11Pathological fractureFAERS: 1US FAERS
12Product use in unapproved indicationFAERS: 1US FAERS
13RicketsFAERS: 1US FAERS
14Abdominal PainSIDER
15AgranulocytosisSIDER
16AlopeciaSIDER
17AmnesiaSIDER
18AngioedemaSIDER
19Arteriosclerosis812508CTD
20ArthralgiaSIDER
21ArthritisSIDER
22ArthropathySIDER
23AsthmaSIDER
24Bone painSIDER
25Burning tongueSIDER
26ConstipationSIDER
27Cramps of lower extremitiesSIDER
28DermatitisSIDER
29DiscomfortSIDER
30DyspepsiaSIDER
31Erythema MultiformeSIDER
32ErythemaSIDER
33Exacerbation of asthmaSIDER
34Feeling abnormalSIDER
35FlatulenceCanada Vigilance: 1Canada Vigilance
SIDER
36GastritisSIDER
37Gastrointestinal PainSIDER
38GlossitisSIDER
39Hallucinations15222671CTD
40HeadacheSIDER
41Hypercalcemia812508CTD
42HypersensitivitySIDER
43InfectionSIDER
44LeukopeniaSIDER
45Musculoskeletal discomfortSIDER
46NauseaSIDER
47Olfaction Disorders15222671CTD
48OsteolysisSIDER
49Osteolytic lesionSIDER
50Osteonecrosis of JawSIDER
51Osteoporosis12862363
17042918
CTD
SIDER
52PancytopeniaSIDER
53Peptic UlcerSIDER
54PruritusSIDER
55Rash follicularSIDER
56Stevens-Johnson Syndrome25811541CTD
SIDER
57UrticariaSIDER
58Vision Disorders15222671CTD
59VomitingSIDER
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.